Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Bevacizumab in Recurrent Glioblastoma
NCT03890952Phase 2Completed
- Sponsor
- Lassen Therapeutics
- Start
- Oct 2018
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in glioblastoma (GBM), sponsored by Lassen Therapeutics. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03890952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03890952.